Literature DB >> 24754245

Management of a pemphigus with IgA and IgG antibodies and coexistent lung cancer.

Petra Cetkovská1, Michaela Komorousová, Iva Lomicová.   

Abstract

Immunoglobulin A (IgA) pemphigus is a clinically distinct variant of pemphigus characterized by intercellular IgA deposition in the epidermis. Recently, an IgA/Immunoglobulin G (IgG) subset of pemphigus with IgA and IgG anti-keratinocyte cell surface antibodies has been described. Both IgA and IgA/IgG pemphigus have been associated with internal malignancies. Above all, monoclonal IgA gammopathy in patients with IgA pemphigus has been reported, and lung cancers in association with IgA/IgG pemphigus have been described. IgA pemphigus can be successfully treated with dapsone, whereas therapeutic management of IgG/IgA pemphigus is not well established yet. We report a rare case of a patient, who developed atypical pemphigus with both IgA and IgG autoantibodies and an underlying lung cancer, successfully treated with corticosteroids and dapsone.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  IgA/IgG pemphigus; dapsone; lung cancer

Mesh:

Substances:

Year:  2014        PMID: 24754245     DOI: 10.1111/dth.12126

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  2 in total

Review 1.  Pemphigus group: overview, epidemiology, mortality, and comorbidities.

Authors:  Khalaf Kridin
Journal:  Immunol Res       Date:  2018-04       Impact factor: 2.829

2.  Clinical and Immunological Study of 30 Cases With Both IgG and IgA Anti-Keratinocyte Cell Surface Autoantibodies Toward the Definition of Intercellular IgG/IgA Dermatosis.

Authors:  Takashi Hashimoto; Kwesi Teye; Koji Hashimoto; Katarzyna Wozniak; Daisuke Ueo; Sakuhei Fujiwara; Kazuhiro Inafuku; Yorihisa Kotobuki; Ines Lakos Jukic; Branka Marinović; Anna Bruckner; Daisuke Tsuruta; Tamihiro Kawakami; Norito Ishii
Journal:  Front Immunol       Date:  2018-05-07       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.